Edition:
International

Medical Equipment, Supplies & Distribution

Page 1

Amplitude Surgical H1 EBITDA Down At 10.8 Million Euros

Wednesday, 24 Mar 2021 12:54pm EDT

March 24 (Reuters) - AMPLITUDE SURGICAL SA ::H1 CONSOLIDATED SALES EUR 45.9 MILLION VERSUS EUR 49.8 MILLION YEAR AGO.LIMITED DECLINE IN EBITDA IN H1(-4.2%) TO €10.8M FOR A MARGIN OF 23.6%.CASH POSITION OF €36.5M AT 31 DECEMBER 2020.HEALTH SITUATION RELATED TO THE COVID-19 PANDEMIC REMAINS DISRUPTED IN THE GROUP'S VARIOUS MARKETS AT THE BEGINNING OF THE SECOND HALF OF THE 2020/2021 FINANCIAL YEAR.IN VIEW OF PROJECTS CARRIED OUT BY GROUP AND TO OPTIMISE ALLOCATION OF ITS CAPITAL, GROUP HAS DECIDED TO STOP ITS ACTIVITIES IN JAPAN.

Tempus Holdings Says Got A Notification From Tempus Group

Friday, 12 Mar 2021 06:41am EST

March 12 (Reuters) - Tempus Holdings Ltd <6880.HK>::GOT A NOTIFICATION FROM TEMPUS GROUP AND TEMPUS LOGISTICS GROUP HOLDING.NOTICE RECEIVED FROM COURT FOR PRE- REORGANIZATION PROCEDURES AGAINST TEMPUS GROUP, TEMPUS LOGISTICS & TEMPUS ASSET MANAGEMENT GROUP.

ASIT biotech Says Its Reorganization Plan Has Been Approved By Majority Of Creditors

Wednesday, 3 Feb 2021 01:00pm EST

Feb 3 (Reuters) - Asit Biotech SA ::REORGANIZATION PLAN HAS BEEN APPROVED BY THE MAJORITY OF CREDITORS.THE DECISION IS NORMALLY EXPECTED ON 9 FEBRUARY 2021.THE COMMERCIAL COURT OF LIÈGE WILL NOW HAVE TO ACCEPT OR REFUSE THE APPROVAL OF THE SAID PLAN.

Mentice Adopts New Regional Structure

Wednesday, 13 Jan 2021 07:00am EST

Jan 13 (Reuters) - Mentice AB ::MENTICE TO ENHANCE ITS ORGANIZATION WITH SEVERAL NEW KEY POSITIONS.EFFECTIVE JANUARY 1(ST), MENTICE HAS ADOPTED A REGIONAL STRUCTURE FOR ITS GO-TO-MARKET ACTIVITIES WITH CREATION OF AN ASIA PACIFIC (APAC) REGION AND A EUROPE AND MIDDLE EAST (EMEA) REGION IN ADDITION TO PREVIOUSLY ESTABLISHED AMERICAS REGION.

Amplifon Approves Project To Redefine Group Corporate Structure

Wednesday, 16 Dec 2020 08:04am EST

Dec 16 (Reuters) - Amplifon SpA ::APPROVED AND KICKED-OFF A PROJECT TO REDEFINE THE GROUP'S CORPORATE STRUCTURE.PROJECT MAINLY AIMED AT SEPARATING OPERATING ACTIVITIES IN ITALY FROM DIRECTION AND MANAGEMENT ACTIVITIES CARRIED OUT BY LISTED PARENT COMPANY.LISTED PARENT COMPANY WILL BE RESPONSIBLE FOR DEVELOPMENT OF STRATEGIC DIRECTION AND FOR MANAGEMENT AND STRATEGIC COORDINATION ACTIVITIES FOR ENTIRE GROUP.OPERATING ACTIVITIES RELATED TO ITALY WILL BE MANAGED BY A DEDICATED COMPANY.FINAL APPROVAL OF PROJECT FOR REDEFINITION OF CORPORATE STRUCTURE BY BOARD IS SCHEDULED FOR MARCH 2021.ALL TRANSACTIONS RELATED TO PROJECT ARE EXPECTED TO BE IMPLEMENTED AND EFFECTIVE BY FIRST HALF OF 2021.PROJECT WILL BE IMPLEMENTED THROUGH CONTRIBUTION IN KIND OF BUSINESS BRANCH RELATED TO OPERATING ACTIVITIES OF ITALY AS CONSIDERATION FOR CAPITAL INCREASE RESERVED TO AMPLIFON, WHICH WILL BE RESOLVED UPON BY COMPANY FULLY OWNED BY LISTED PARENT ENTITY.

China Regenerative Medicine Says Change Of Domicile, Capital Reorganisation To Not Proceed

Friday, 27 Nov 2020 05:13am EST

Nov 27 (Reuters) - China Regenerative Medicine International Ltd <8158.HK>::CHANGE OF DOMICILE, CAPITAL REORGANISATION TO NOT PROCEED.

PZ Cormay Buys 3.9 Mln Shares Unit Orphée For CHF 1.2 Mln, Completes Consolidation

Tuesday, 17 Nov 2020 10:07am EST

Nov 17 (Reuters) - PZ Cormay SA ::BUYS 3.9 MILLION SHARES IN ITS UNIT ORPHÉE FOR CHF 1.2 MILLION.SHARE ACQUISITION IS LAST STAGE OF UNIT'S CONSOLIDATION AT CAPITAL LEVEL.

Simavita Says Now Well Prepared To Roll Out Its Reorganisation Strategy

Tuesday, 30 Jun 2020 07:49pm EDT

July 1 (Reuters) - Simavita Ltd ::SIMAVITA- NOW WELL PREPARED TO ROLL OUT ITS REORGANISATION STRATEGY.SIMAVITA- ENGAGED & SIGNIFICANTLY PROGRESSED TALKS WITH MAJOR INDUSTRY PARTNERS.

IGEA Pharma Announces Nomination Of Lieven Baten For Election As Non-Executive Director At Upcoming General Meeting

Tuesday, 2 Jun 2020 04:50pm EDT

June 2 (Reuters) - IGEA Pharma NV ::EQS-ADHOC: IGEA ANNOUNCES CHANGES IN ITS BOARD.IGEA PHARMA - NOMINATION OF LIEVEN BATEN FOR ELECTION AS NON-EXECUTIVE DIRECTOR OF IGEA AT UPCOMING GENERAL MEETING ON 3 JULY 2020.

Allegra Orthopaedics Says Covid-19 To Negatively Impact Performance For FY2020

Wednesday, 25 Mar 2020 11:57pm EDT

March 26 (Reuters) - Allegra Orthopaedics Ltd ::RISE OF COVID-19 PANDEMIC IN AUSTRALIA WILL HAVE A DIRECT & NEGATIVE IMPACT ON ALLEGRA'S FINANCIAL PERFORMANCE FOR FY2020.ALLEGRA'S REVENUES GENERATED FROM ITS ORTHOPAEDIC DIVISION WILL BE MATERIALLY AND NEGATIVELY IMPACTED.UNABLE TO ESTIMATE VALUE OF COVID-19 IMPACT.BELIEVES WILL RECOVER BACK TO NORMAL OPERATING CONDITIONS AS PANDEMIC COMES UNDER CONTROL.TOOK MEASURES LIKE SALARY REDUCTIONS OF SENIOR STAFF, REDUCE STAFF WORK HOURS &STANDING DOWN STAFF UNTIL SITUATION UNDER CONTROL.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary